


Highlights of This Issue 1299

SPECIAL FEATURES

CCR Translations

- 1301** Bone Disease in Myeloma: The Claws of CRAB
Rafael Fonseca and Tania Jain
See related article, p. 1378
- 1304** Surgical Guidance in Prostate Cancer: "From Molecule to Man" Translations
Fijs W.B. van Leeuwen and Henk G. van der Poel
See related article, p. 1403


CCR Drug Updates

- 1307** FDA Approval of Gefitinib for the Treatment of Patients with Metastatic *EGFR* Mutation-Positive Non-Small Cell Lung Cancer
 Dickran Kazandjian, Gideon M. Blumenthal, Weishi Yuan, Kun He, Patricia Keegan, and Richard Pazdur


Molecular Pathways

- 1313** Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy
Maurizio Scaltriti, Moshe Elkabets, and José Baselga

Review

- 1318** Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example
 Jeffrey R. Sachs, Kapil Mayawala, Satvik Gadamssetty, Soonmo Peter Kang, and Dinesh P. de Alwis

CLINICAL TRIAL BRIEF REPORT

- 1325** An Investigator-Initiated Open-Label Trial of Sonidegib in Advanced Basal Cell Carcinoma Patients Resistant to Vismodegib
 Christina Danial, Kavita Y. Sarin, Anthony E. Oro, and Anne Lynn S. Chang


CANCER THERAPY: CLINICAL

- 1330** Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients—Report of a Phase I/IIa Clinical Trial
Amandine Legat, H el ene Maby-El Hajjami, Petra Baumgaertner, Laur ene Cagnon, Samia Abed Maillard, Christine Geldhof, Emanuela M. Iancu, Luc Lebon, Philippe Guillaume, Danijel Dojcinovic, Olivier Michielin, Emanuela Romano, Gr egoire Berthod, Donata Rimoldi, Fr ed eric Triebel, Immanuel Luescher, Nathalie Rufer, and Daniel E. Speiser
- 1341** Correlating Surrogate Endpoints with Overall Survival at the Individual Patient Level in *BRAF*^{V600E}-Mutated Metastatic Melanoma Patients Treated with Vemurafenib
Emily C. Zabor, Glenn Heller, Lawrence H. Schwartz, and Paul B. Chapman
- 1348** A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors
Kyriakos P. Papadopoulos, Robin Kate Kelley, Anthony W. Tolcher, Albiruni R. Abdul Razak, Katherine Van Loon, Amita Patnaik, Philippe L. Bedard, Ariceli A. Alfaro, Muralidhar Beeram, Lieve Adriaens, Carrie M. Brownstein, Israel Lowy, Ana Kostic, Pamela A. Trail, Bo Gao, A. Thomas DiCioccio, and Lillian L. Siu
- 1356** Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer
Bruce Montgomery, Mario A. Eisenberger, Matthew B. Rettig, Franklin Chu, Roberto Pili, Joseph J. Stephenson, Nicholas J. Vogelzang, Alan J. Koletsky, Luke T. Nordquist, William J. Edenfield, Khalid Mamlouk, Karen J. Ferrante, and Mary-Ellen Taplin
- 1364** Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors
Melinda S. Merchant, Matthew Wright, Kristin Baird, Leonard H. Wexler, Carlos Rodriguez-Galindo, Donna Bernstein, Cindy Delbrook, Maya Lodish, Rachel Bishop, Jedd D. Wolchok, Howard Streicher, and Crystal L. Mackall

Table of Contents

- 1371** **HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer**
Chun-Fang Xu, Toby Johnson, Xiaojing Wang, Chris Carpenter, Alan P. Graves, Liling Warren, Zhengyu Xue, Karen S. King, Dana J. Fraser, Sandy Stinnett, Linda P. Briley, Ionel Mitrica, Colin F. Spraggs, Matthew R. Nelson, Hiroomi Tada, Andreas du Bois, Thomas Powles, Neil Kaplowitz, and Lini N. Pandite

- 1378** **Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study**
Noopur Rajee, Robert Vescio, Charles W. Montgomery, Ashraf Badros, Nikhil Munshi, Richard Orłowski, Joseph T. Hadala, Ghulam Warsi, Eliza Argonza-Aviles, Solveig G. Ericson, and Kenneth C. Anderson
See related commentary, p. 1301

- 1385** **Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma**
 Masafumi Ikeda, Takuji Okusaka, Shuichi Mitsunaga, Hideki Ueno, Toshiyuki Tamai, Takuya Suzuki, Seiichi Hayato, Tadashi Kadowaki, Kiwamu Okita, and Hiromitsu Kumada

PERSONALIZED MEDICINE AND IMAGING

- 1395** **Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor Therapy**
Cesar A. Santa-Maria, Amanda Blackford, Anne T. Nguyen, Todd C. Skaar, Santosh Philips, Steffi Oesterreich, James M. Rae, Zeruesenay Desta, Jason Robarge, Norah Lynn Henry, Anna M. Storniolo, Daniel F. Hayes, Roger S. Blumenthal, Pamela Ouyang, Wendy S. Post, David A. Flockhart, Vered Stearns, and Consortium on Breast Cancer Pharmacogenomics (COBRA)

- 1403** **Fluorescent Image-Guided Surgery with an Anti-Prostate Stem Cell Antigen (PSCA) Diabody Enables Targeted Resection of Mouse Prostate Cancer Xenografts in Real Time**
Geoffrey A. Sonn, Andrew S. Behesnilian, Ziyue Karen Jiang, Kirstin A. Zettlitz, Eric J. Lepin, Laurent A. Bentolila, Scott M. Knowles, Daniel Lawrence, Anna M. Wu, and Robert E. Reiter
See related commentary, p. 1304

- 1413** **Patients with a High Polygenic Risk of Breast Cancer do not have an Increased Risk of Radiotherapy Toxicity**
Leila Dorling, Gillian C. Barnett, Kyriaki Michailidou, Charlotte E. Coles, Neil G. Burnet, John Yarnold, Rebecca M. Elliott, Alison M. Dunning, Paul D.P. Pharoah, and Catharine M. West


- 1421** **ERR α Is a Marker of Tamoxifen Response and Survival in Triple-Negative Breast Cancer**
Subrata Manna, Josefine Bostner, Yang Sun, Lance D. Miller, Anya Alayev, Naomi S. Schwartz, Elin Lager, Tommy Fornander, Bo Nördenskjöld, Jane J. Yu, Olle Stål, and Marina K. Holz

CANCER THERAPY: PRECLINICAL

- 1432** **IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF- κ B Activation**
Zhuonan Zhuang, Huai-Qiang Ju, Mitzi Aguilar, Takashi Gocho, Hao Li, Tomonori Iida, Harold Lee, Xiaoqiang Fan, Haijun Zhou, Jianhua Ling, Zhongkui Li, Jie Fu, Min Wu, Min Li, Davide Melisi, Yoichiro Iwakura, Kesen Xu, Jason B. Fleming, and Paul J. Chiao

- 1445** **A Novel Bioavailable BH3 Mimetic Efficiently Inhibits Colon Cancer via Cascade Effects of Mitochondria**
 Xuefeng Wang, Chen Zhang, Xiangming Yan, Bin Lan, Jianyong Wang, Chongyang Wei, Xingxin Cao, Renxiao Wang, Jianhua Yao, Tao Zhou, Mi Zhou, Qiaoling Liu, Biao Jiang, Pengfei Jiang, Santosh Kesari, Xinjian Lin, and Fang Guo

- 1459** **Combination of Photodynamic Therapy and Specific Immunotherapy Efficiently Eradicates Established Tumors**
Jan Willem Kleinovink, Pieter B. van Driel, Thomas J. Snoeks, Natasa Prokopi, Marieke F. Fransen, Luis J. Cruz, Laura Mezzanotte, Alan Chan, Clemens W. Löwik, and Ferry Ossendorp

- 1469** **Balancing Efficacy and Safety of an Anti-DLL4 Antibody through Pharmacokinetic Modulation**
 Jessica A. Couch, Gu Zhang, Joseph C. Beyer, Christina L. Zuch de Zafra, Priyanka Gupta, Amrita V. Kamath, Nicholas Lewin-Koh, Jacqueline Tarrant, Krishna P. Allamneni, Gary Cain, Sharon Yee, Sarajane Ross, Ryan Cook, Siao Ping Tsai, Jane Ruppel, John Brady Ridgway, Maciej Paluch, Philip E. Hass, Jayme Franklin, and Minhong Yan

BIOLOGY OF HUMAN TUMORS

- 1480** **Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia**
Stéphanie Poulain, Christophe Roumier, Aurélie Venet-Caillault, Martin Figeac, Charles Herbaux, Guillemette Marot, Emmanuelle Doye, Elisabeth Bertrand, Sandrine Geffroy, Frédéric Lepretre, Olivier Nibourel, Audrey Decambon, Eileen Mary Boyle, Aline Renneville, Sabine Tricot, Agnès Daudignon, Bruno Quesnel, Patrick Duthilleul, Claude Preudhomme, and Xavier Leleu

Table of Contents

1489 Prognostic Utility of Molecular Factors by Age at Diagnosis of Colorectal Cancer

Nadine J. McCleary, Kaori Sato, Reiko Nishihara, Kentaro Inamura, Teppei Morikawa, Xuehong Zhang, Kana Wu, Mai Yamauchi, Sun A. Kim, Yasutaka Sukawa, Kosuke Mima, Zhi Rong Qian, Charles S. Fuchs, Shuji Ogino, and Jeffrey A. Meyerhardt

1499 RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors

Sherene Loi, Sathana Dushyanthen, Paul A. Beavis, Roberto Salgado, Carsten Denkert, Peter Savas, Susan Combs, David L. Rimm, Jennifer M. Giltane, Monica V. Estrada, Violeta Sánchez, Melinda E. Sanders, Rebecca S. Cook, Mark A. Pilkinton, Simon A. Mallal, Kai Wang, Vincent A. Miller, Phil J. Stephens, Roman Yelensky, Franco D. Doimi, Henry Gómez, Sergey V. Ryzhov, Phillip K. Darcy, Carlos L. Arteaga, and Justin M. Balko

1510 The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer

Himisha Beltran, Adam Jendrisak, Mark Landers, Juan Miguel Mosquera, Myriam Kossai, Jessica Louw, Rachel Krupa, Ryon P. Graf, Nicole A. Schreiber, David M. Nanus, Scott T. Tagawa, Dena Marrinucci, Ryan Dittamore, and Howard I. Scher

1520 Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers

Ana M. Aparicio, Li Shen, Elsa Li Ning Tapia, Jing-Fang Lu, Hsiang-Chun Chen, Jiexin Zhang, Guanglin Wu, Xuemei Wang, Patricia Troncoso, Paul Corn, Timothy C. Thompson, Bradley Broom, Keith Baggerly, Sankar N. Maity, and Christopher J. Logothetis

1531 Flightless I Homolog Represses Prostate Cancer Progression through Targeting Androgen Receptor Signaling

Tao Wang, Wen Song, Yuan Chen, Ruibao Chen, Zhuo Liu, Licheng Wu, Mingchao Li, Jun Yang, Liang Wang, Jihong Liu, Zhangqun Ye, Chenguang Wang, and Ke Chen


 AC icon indicates Author Choice

 CME icon indicates that this article is available for continuing medical education credit at <http://cme.aacrjournals.org>

For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover shows a model of pazopanib (light pink carbons) bound to HLA-B*57:01. Abacavir (orange carbons) from the crystal structure of abacavir bound to HLA-B*57:01 (grey carbons) is overlaid for reference. For details, see the article by Xu and colleagues on page 1371 of this issue.



Clinical Cancer Research

22 (6)

Clin Cancer Res 2016;22:1299-1544.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/22/6>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/22/6>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.